Home » ALEXION ANNOUNCES RESULTS OF PRIMO-CABG2 TRIAL
ALEXION ANNOUNCES RESULTS OF PRIMO-CABG2 TRIAL
Alexion Pharmaceuticals has reported results from its Phase III PRIMO-CABG2 clinical trial with pexelizumab. The study revealed that the drug reduced the primary endpoint, but did not achieve statistical significance for the co-primary endpoint of death or myocardial infarction through POD 30.
Pexelizumab, a terminal complement inhibitor, is a monoclonal antibody fragment that inhibits complement-mediated tissue damage. The trial enrolled moderate-to-high risk coronary artery bypass graft surgery patients. According to the company, pexelizumab appeared to be well-tolerated with an adverse event profile comparable to placebo.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May